Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects meeting all of the following criteria will be considered for admission to the study:~1. Male or female subject aged between 8 and 23 years of age; only patients up to the age of 23 will be studied at Childrens Hospital Los Angeles~2. Electrophoretic diagnosis of sickle cell disease;~3. Sudden onset of acute pain involving \>=1 sites typical of vaso-occlusive crisis (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest, abdomen, or back that can not be explained by other complications of sickle cell disease or by a cause other than sickle cell disease.);~4. Severe pain requiring parenteral analgesics and hospitalization.~5. Informed consent obtained from a legal representative or from subjects 18 years of age or older before enrollment;~6. Being willing and able to be followed for at least 30 days for evaluation.~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~1. Clinically significant bleeding;~2. Current drug abuse or participation in methadone program;~3. Episode of pain requiring hospitalization within 2 weeks prior to current admission;~4. Other complications of sickle cell disease including cerebrovascular accident, pulmonary hypertension, or seizure;~5. Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding;~6. Blood pressure less than 25th percentile for the subject's age and sex on admission or at the time of screening;~7. Methemoglobinemia \>3%;~8. Anemia with hemoglobin level less than 6 g/dL;~9. Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;~10. History of allergy to nitrites or allergy to other substances characterized by dyspnea and cyanosis;~11. Treatment with allopurinol, a medication that could interfere with nitrite metabolism, within the past 30 days before screening;~12. Treatment with any investigational drug within the past 30 days;~13. Significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months;~14. Any subject judged by the clinical investigator or study manager to be inappropriate for the study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- No drug (Type: NO_INTERVENTION): No study drug administered
- Sodium nitrite injection, USP (Type: EXPERIMENTAL): Administration if sodium nitrite injection, USP

Based on this trial design, predict the completion outcome and termination type (if applicable).